Teleflex today announced that is has completed the previously announced acquisition of substantially all of the Vascular Intervention business of Biotronik.
The company notes in a press release that the acquisition adds a broad portfolio of therapeutic products to Teleflex’s portfolio of interventional access products.
On 27 February 2025, Teleflex announced its entry into a definitive agreement to acquire substantially all of Biotronik’s Vascular Intervention business. Under the terms of the agreement, Teleflex acquired the Vascular Intervention business for a cash payment of €760 million, less certain adjustments as provided in the purchase agreement, including certain working capital not transferring and other customary adjustments.
“We are pleased to announce the completion of the acquisition of substantially all of the Vascular Intervention business of Biotronik earlier than expected” said Liam Kelly, chairman, president and chief executive officer of Teleflex. “The acquisition will significantly enhance our global presence in the cath lab, expand our suite of innovative technologies, and improve patient care. We believe the acquisition will allow us to position this advanced coronary portfolio alongside our existing Interventional business and establish our global footprint in the fast-growing peripheral intervention market. The acquired business is rooted in robust research and development, clinical expertise, and global manufacturing capabilities, which we believe will further bolster Teleflex’s innovation pipeline, and position the company to participate in the emerging potential for resorbable scaffold technologies. We will provide additional details on our second quarter earnings conference call.”
The acquired Vascular Intervention business consists of a portfolio for coronary and peripheral interventions performed in the cath lab and interventional radiology suites. In coronary vascular interventions, Teleflex details that key products include the Pantera Lux drug-coated balloon catheter, the novel PK Papyrus covered coronary stent for acute coronary artery perforations, and the Orsiro Mission drug-eluting stent, an ultrathin drug-eluting stent with differentiated clinical features. For peripheral interventions, the portfolio includes the Passeo-18 Lux peripheral drug-coated balloon catheter, Dynetic-35 balloon-expandable cobalt chromium stent, the Pulsar-18 T3 self-expanding 4F stent, and the Oscar peripheral multifunctional catheter system.
Teleflex shares that the acquisition will also allow the company the opportunity to invest in and expand the clinical trial programme for Freesolve, a sirolimus-eluting resorbable metallic scaffold (RMS) technology, including plans to initiate a US pivotal study. Freesolve, which received its CE mark in February 2024, is indicated in CE-mark accepting countries for de novo coronary artery lesions. The combination of temporary scaffolding with drug delivery is anticipated to address the current trend in interventional coronary and endovascular procedures toward leaving behind less permanent hardware. As demonstrated in the BIOMAG-I study, Freesolve RMS demonstrated resorption after 12 months, a target lesion failure rate comparable to contemporary drug-eluting stents, and no definite or probable scaffold thrombosis. The European pivotal BIOMAG-II study is now enrolling.
